Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Hector Leon-Figueroa

Internal Medicine San Juan, PR Medical Doctor

NPI 1225020704 CMS profile 938953

U-32 Las Lomas, San Juan, PR 00921

Open in the dashboard

General payments

$5,745

296 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Hector Leon-Figueroa of San Juan, PR is reported in the CMS Open Payments database as having received $5,745 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $20 1
2022 General $146 5
2021 General $956 46
2020 General $1,757 97
2019 General $2,867 147

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hector Leon-Figueroa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hector Leon-Figueroa were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hector Leon-Figueroa Internal Medicine median Middle half National median
2019 $2,867 $159 $48–$570 $163
2020 $1,757 $119 $33–$402 $114
2021 $956 $135 $37–$521 $132
2022 $146 $141 $42–$496 $149
2023 $20 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $1,018 52 payments
  2. E.R. Squibb & Sons, L.L.C. $851 54 payments
  3. AstraZeneca Pharmaceuticals LP $798 45 payments
  4. AbbVie, Inc. $621 27 payments
  5. Genentech USA, Inc. $515 24 payments
  6. Eli Lilly Export S.A. Puerto Rico Branch $463 22 payments
  7. Merck Sharp & Dohme Corporation $339 17 payments
  8. Amgen Inc. $233 13 payments
  9. Janssen Biotech, Inc. $189 2 payments
  10. Genzyme Corporation $167 9 payments
  11. Other $552 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,310 289 payments
  2. Education $436 7 payments
Products named General payments · program years 2019–2023
  1. OPDIVO $531 29 payments
  2. IMBRUVICA $471 17 payments
  3. VERZENIO $463 22 payments
  4. CYRAMZA $396 22 payments
  5. TECENTRIQ $361 16 payments
  6. KEYTRUDA $322 16 payments
  7. XARELTO $307 10 payments
  8. ERLEADA $297 17 payments
  9. CALQUENCE $226 13 payments
  10. XGEVA $210 12 payments
  11. Other $3,406 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,646

Median for Internal Medicine: 777

Drug cost

$5,815,304

Median for Internal Medicine: $73,373

Branded share of claims

38%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Promacta Eltrombopag Olamine Brand 58 $781,222
Xtandi Enzalutamide Brand 55 $779,700
Cabometyx Cabozantinib S-Malate Brand 26 $696,795
Erleada Apalutamide Brand 34 $511,918
Lenalidomide Generic 31 $468,823
Verzenio Abemaciclib Brand 28 $433,879
Thalomid Thalidomide Brand 30 $412,394
Imbruvica Ibrutinib Brand 20 $332,078
Lupron Depot Leuprolide Acetate Brand 47 $285,770
Revlimid Lenalidomide Brand 20 $265,531

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$4,225

Medicare's payments for the services billed

Medicare patients

19

Average age 76

Services billed

47

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record